These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 17584314

  • 21. Intravenous immunoglobulin preparation type: association with outcomes for patients with acute Kawasaki disease.
    Manlhiot C, Yeung RS, Chahal N, McCrindle BW.
    Pediatr Allergy Immunol; 2010 May; 21(3):515-21. PubMed ID: 20546528
    [Abstract] [Full Text] [Related]

  • 22. High-dose intravenous immunoglobulin downregulates the activated levels of inflammatory indices except erythrocyte sedimentation rate in acute stage of Kawasaki Disease.
    Lee KY, Lee HS, Hong JH, Han JW, Lee JS, Whang KT.
    J Trop Pediatr; 2005 Apr; 51(2):98-101. PubMed ID: 15677370
    [Abstract] [Full Text] [Related]

  • 23. Assessment of intravenous immunoglobulin non-responders in Kawasaki disease.
    Hwang JY, Lee KY, Rhim JW, Youn YS, Oh JH, Han JW, Lee JS, Burgner D.
    Arch Dis Child; 2011 Nov; 96(11):1088-90. PubMed ID: 20551193
    [Abstract] [Full Text] [Related]

  • 24. Clinical responses of patients with Kawasaki disease to different brands of intravenous immunoglobulin.
    Tsai MH, Huang YC, Yen MH, Li CC, Chiu CH, Lin PY, Lin TY, Chang LY.
    J Pediatr; 2006 Jan; 148(1):38-43. PubMed ID: 16423595
    [Abstract] [Full Text] [Related]

  • 25. [Risk factors for coronary artery lesions in children with Kawasaki disease].
    Li Y, Wang XM, Liu YL, Shi K, Yang YF, Guo YH.
    Zhongguo Dang Dai Er Ke Za Zhi; 2012 Dec; 14(12):938-41. PubMed ID: 23234782
    [Abstract] [Full Text] [Related]

  • 26. Prognostic impact of vascular leakage in acute Kawasaki disease.
    Terai M, Honda T, Yasukawa K, Higashi K, Hamada H, Kohno Y.
    Circulation; 2003 Jul 22; 108(3):325-30. PubMed ID: 12835221
    [Abstract] [Full Text] [Related]

  • 27. Decreased nitric oxide production after intravenous immunoglobulin treatment in patients with Kawasaki disease.
    Wang CL, Wu YT, Lee CJ, Liu HC, Huang LT, Yang KD.
    J Pediatr; 2002 Oct 22; 141(4):560-5. PubMed ID: 12378198
    [Abstract] [Full Text] [Related]

  • 28. A cost-benefit analysis of intravenous immunoglobulin treatment in children with Kawasaki disease.
    Arj-ong S, Chotivitayatarakorn P, Lertsapcharoen P, Khongphatthanayothin A, Thisyakorn C.
    J Med Assoc Thai; 2003 Jun 22; 86 Suppl 2():S179-88. PubMed ID: 12929987
    [Abstract] [Full Text] [Related]

  • 29. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease.
    Wang Y, Wang W, Gong F, Fu S, Zhang Q, Hu J, Qi Y, Xie C, Zhang Y.
    Arthritis Rheum; 2013 Mar 22; 65(3):805-14. PubMed ID: 23440694
    [Abstract] [Full Text] [Related]

  • 30. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset.
    Fukunishi M, Kikkawa M, Hamana K, Onodera T, Matsuzaki K, Matsumoto Y, Hara J.
    J Pediatr; 2000 Aug 22; 137(2):172-6. PubMed ID: 10931407
    [Abstract] [Full Text] [Related]

  • 31. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease.
    Lee TJ, Kim KH, Chun JK, Kim DS.
    Yonsei Med J; 2008 Oct 31; 49(5):714-8. PubMed ID: 18972590
    [Abstract] [Full Text] [Related]

  • 32. [Expression of sICAM-1 in children with intravenous immunoglobulin-resistant Kawasaki disease].
    Liu F, Ding Y, Yin W.
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Dec 31; 15(12):1109-12. PubMed ID: 24342209
    [Abstract] [Full Text] [Related]

  • 33. Intravenous immunoglobulin does not increase FcgammaRIIB expression on monocytes/macrophages during acute Kawasaki disease.
    Ichiyama T, Ueno Y, Hasegawa M, Ishikawa Y, Matsubara T, Furukawa S.
    Rheumatology (Oxford); 2005 Mar 31; 44(3):314-7. PubMed ID: 15572393
    [Abstract] [Full Text] [Related]

  • 34. Clinical relevance of the risk factors for coronary artery lesions in Kawasaki disease.
    Weng KP, Hsieh KS, Huang SH, Ou SF, Ma CY, Ho TY, Lai CR, Ger LP.
    Kaohsiung J Med Sci; 2012 Jan 31; 28(1):23-9. PubMed ID: 22226058
    [Abstract] [Full Text] [Related]

  • 35. [Efficacy and safety of glucocorticoids in addition to intravenous immunoglobulin in the initial treatment of Kawasaki disease: a meta-analysis of randomized trials].
    Hu JW, Zhou ZS, Yang L, Zheng CN, Wang KD.
    Zhonghua Yi Xue Za Zhi; 2011 May 17; 91(18):1259-64. PubMed ID: 21756798
    [Abstract] [Full Text] [Related]

  • 36. Predicting IVIG resistance in UK Kawasaki disease.
    Davies S, Sutton N, Blackstock S, Gormley S, Hoggart CJ, Levin M, Herberg JA.
    Arch Dis Child; 2015 Apr 17; 100(4):366-8. PubMed ID: 25670405
    [Abstract] [Full Text] [Related]

  • 37. Immunoglobulin G values before treatment are correlated with the responsiveness to initial intravenous immunoglobulin therapy for Kawasaki disease.
    Yanagimoto K, Nomura Y, Masuda K, Hirabayashi M, Morita Y, Yoshishige M, Ueno K, Eguchi T, Kawano Y.
    Int Arch Allergy Immunol; 2014 Apr 17; 164(2):83-8. PubMed ID: 24903098
    [Abstract] [Full Text] [Related]

  • 38. Epidemiologic study of Kawasaki disease at a single hospital in Daejeon, Korea (1987 through 2000).
    Lee KY, Han JW, Lee HS, Hong JH, Hahn SH, Lee JS, Whang KT.
    Pediatr Infect Dis J; 2004 Jan 17; 23(1):52-5. PubMed ID: 14743047
    [Abstract] [Full Text] [Related]

  • 39. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial.
    Sundel RP, Baker AL, Fulton DR, Newburger JW.
    J Pediatr; 2003 Jun 17; 142(6):611-6. PubMed ID: 12838187
    [Abstract] [Full Text] [Related]

  • 40. Value of neutrophil-lymphocyte ratio in predicting outcomes in Kawasaki disease.
    Ha KS, Lee J, Jang GY, Lee J, Lee KC, Son CS, Lee JW.
    Am J Cardiol; 2015 Jul 15; 116(2):301-6. PubMed ID: 25975725
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.